IC
Ikarian Capital Portfolio holdings
AUM
$302M
1-Year Return
65.21%
This Quarter Return
+11.71%
1 Year Return
+65.21%
3 Year Return
+441.33%
5 Year Return
+548.26%
10 Year Return
–
AUM
$302M
AUM Growth
-$4.71M
(-1.5%)
Cap. Flow
-$13.5M
Cap. Flow
% of AUM
-4.45%
Top 10 Holdings %
Top 10 Hldgs %
44.95%
Holding
160
New
20
Increased
14
Reduced
32
Closed
33
Top Buys
| 1 |
Cidara Therapeutics
CDTX
|
+$10.5M |
| 2 |
Apogee Therapeutics
APGE
|
+$10.1M |
| 3 |
Alnylam Pharmaceuticals
ALNY
|
+$8.15M |
| 4 |
Insmed
INSM
|
+$7.95M |
| 5 |
Cogent Biosciences
COGT
|
+$7.44M |
Top Sells
| 1 |
SPDR S&P 500 ETF Trust
SPY
|
+$14M |
| 2 |
Tarsus Pharmaceuticals
TARS
|
+$11.7M |
| 3 |
BPMC
Blueprint Medicines
BPMC
|
+$10.1M |
| 4 |
Ultragenyx Pharmaceutical
RARE
|
+$7.86M |
| 5 |
Scholar Rock
SRRK
|
+$6.91M |
Sector Composition
| 1 | Healthcare | 99.76% |
| 2 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Cidara Therapeutics
CDTX
$1.61B
| $22.6M | 4.35% |
464,488
+215,548
| +87% | +$10.5M |
|
|
2
Alnylam Pharmaceuticals
ALNY
$61.5B
| $18.5M | 3.54% |
56,594
+25,000
| +79% | +$8.15M |
|
|
3
Insmed
INSM
$30.8B
| $16.5M | 3.17% |
163,751
+78,951
| +93% | +$7.95M |
|
|
VRNA
4
Verona Pharma
VRNA
$9.2B
| $13.9M | 2.67% |
146,831
+16,831
| +13% | +$1.59M |
|
5
Crinetics Pharmaceuticals
CRNX
$3.3B
| $12.5M | 2.39% |
433,431
-90,000
| -17% | -$2.59M |
|
6
Akero Therapeutics
AKRO
$3.59B
| $11.7M | 2.25% |
220,000
-25,000
| -10% | -$1.33M |
|
7
Praxis Precision Medicines
PRAX
$847M
| $11.6M | 2.24% |
276,950
+131,448
| +90% | +$5.53M |
|
|
8
Apogee Therapeutics
APGE
$2.23B
| $10.1M | 1.94% |
+232,047
| New | +$10.1M |
|
9
Vaxcyte
PCVX
$4.15B
| $9.92M | 1.9% |
305,000
+105,000
| +53% | +$3.41M |
|
|
ACOG
10
Alpha Cognition Inc. Common Stock
ACOG
$156M
| $8.56M | 1.64% |
917,867
-50,000
| -5% | -$467K |
|
|
11
Tarsus Pharmaceuticals
TARS
$2.19B
| $7.96M | 1.53% |
196,536
-288,485
| -59% | -$11.7M |
|
12
Cytokinetics
CYTK
$6.22B
| $7.71M | 1.48% |
233,464
+83,482
| +56% | +$2.76M |
|
13
Sarepta Therapeutics
SRPT
$1.87B
| $7.68M | 1.48% |
449,087
+280,000
| +166% | +$4.79M |
|
14
TG Therapeutics
TGTX
$5.05B
| $7.56M | 1.45% |
209,938
-127
| -0.1% | -$4.57K |
|
|
15
Cogent Biosciences
COGT
$1.78B
| $7.44M | 1.43% |
+1,035,528
| New | +$7.44M |
|
16
Viridian Therapeutics
VRDN
$1.6B
| $6.57M | 1.26% |
469,949
-25,000
| -5% | -$350K |
|
17
Arvinas
ARVN
$575M
| $6.26M | 1.2% |
850,000
+620,100
| +270% | +$4.56M |
|
18
Forte Biosciences
FBRX
$135M
| $6.16M | 1.18% |
476,443
-132,782
| -22% | -$1.72M |
|
19
Vir Biotechnology
VIR
$713M
| $5.38M | 1.03% |
1,068,062
| – | – |
|
20
Catalyst Pharmaceutical
CPRX
$2.42B
| $4.55M | 0.87% |
209,649
-40,000
| -16% | -$868K |
|
21
Delcath Systems
DCTH
$389M
| $4.38M | 0.84% |
322,390
+222,025
| +221% | +$3.02M |
|
22
Jazz Pharmaceuticals
JAZZ
$7.7B
| $4.24M | 0.82% |
+40,000
| New | +$4.24M |
|
23
CG Oncology
CGON
$2.53B
| $4.03M | 0.77% |
+155,000
| New | +$4.03M |
|
24
Neuronetics
STIM
$228M
| $3.84M | 0.74% |
1,099,700
-300
| -0% | -$1.05K |
|
25
Structure Therapeutics
GPCR
$1.2B
| $3.8M | 0.73% |
183,085
-81,000
| -31% | -$1.68M |
|